cxicities 
Level 1,2: Stop irterf ercr.. When sycptcrs < Level 
1, restar: at QCI schedule. If progressive, 
recurrent cr persi ster.t, held dcse until symptoms 
resolve, then dcse reduce to 50% cf the original 
dcse cr. 2-CI schedule; Neurotoxicity Level 2: 
Oisccr.cir.ue unterfercr. 
11.2 Conditioning Reciter. lose Adj ustnents for Cbese 
For cyclcphosphaai de dosages a correction in weight 
'-•ill he race if actual body weight exceeds ideal body 
■-eight by 20%. In that situation the weight used to 
calculate chenc therapy dosage will be: actual body 
weight— ideal body weight) /2 - ideal body weight. 
11.2 S— IS J 
0-rade 2 toxicity 'see appendix 7, the teratologic 
portion will net be utilized for dcse adjustments) 
thought to be related to G-CSF, will necessitate a 5C% 
dosage reduction. If grade 2 toxicity persists for 
seven days or advances to grade 4 toxicity, G-CSF will 
be discontinued and the patient will not re-start the 
redi cation. 
11.4 Pest- transplant Interfere r. alpha 'for toxicity levels 
see appendix I, 
Intolerable fatigue and anorexia 
Level 1: lose reduce to 50% cf the original dose; 
if no irprcverer.t, discontinue. 
All other toxicities 
Level 1,2: Stop interferon. When syrpters < Level 
1, restart at 50% of the original dcse; 
Neurotoxicity Level 2: I is continue interferon. 
.2.0 Hazards and liscctfcrts 
Letailed toxicity data or. all required non-standard study 
drugs are given for each dreg in appendix D. A detailed 
toxicity profile of total body irradiation at the doses and 
rates er cloyed in this study are also given in appendix C. 
The na^or hazard of this protocol is the rortality 
associated with cytc reductive therapy and high dose 
cyclcphcspharide 131 and transplant which ranges fret 1-5% 
[ 170 ] 
Recombinant DNA Research, Volume 16 
